Pipeline tracker

Which company is registered as the sponsor of studies on which compound, and at which phase. Built from ClinicalTrials.gov registry entries, with links to company and regulator pages where we have them. Informational only.

Ask Tina

Tina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.

Dates are the primary completion dates entered in the registry. They are not company forecasts or guidance on when results will be published. Phases and counts come straight from the registry and change as sponsors update it.

Eli Lilly and Company

RetatrutideHighest registered phase: Phase 3 · 32 registered Eli Lilly and Company-sponsored studiesNot stated: 1 · Phase 1: 14 · Phase 2: 3 · Phase 3: 14Registered primary completion dates (registry entries, not company forecasts):2026-10 · Phase 3 · NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)2026-11 · Phase 3 · NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity2027-01 · Phase 1 · NCT06982859: A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus2027-07 · Phase 3 · NCT07232719: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight2027-09 · Phase 3 · NCT07035093: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainLilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialLilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

OrforglipronHighest registered phase: Phase 3 · 49 registered Eli Lilly and Company-sponsored studiesPhase 1: 20 · Phase 2: 2 · Phase 3: 27Status: FDA approval announced Apr 1, 2026 (company release)Registered primary completion dates (registry entries, not company forecasts):2027-02 · Phase 3 · NCT06672549: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)2027-05 · Phase 3 · NCT07613307: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting2027-08 · Phase 3 · NCT06972472: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes2027-08 · Phase 3 · NCT06972459: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity2027-08 · Phase 3 · NCT06993792: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesFDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

TirzepatideHighest registered phase: Phase 4 · 80 registered Eli Lilly and Company-sponsored studiesPhase 1: 25 · Phase 2: 11 · Phase 3: 36 · Phase 4: 8Registered primary completion dates (registry entries, not company forecasts):2026-11 · Phase 3 · NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity2026-11 · Phase 3 · NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight2026-11 · Phase 3 · NCT06962280: A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight2026-11 · Phase 1 · NCT07299084: A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus2026-12 · Phase 1 · NCT07803744: A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityNovo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial

EloralintideHighest registered phase: Phase 3 · 18 registered Eli Lilly and Company-sponsored studiesPhase 1: 9 · Phase 2: 4 · Phase 3: 5Registered primary completion dates (registry entries, not company forecasts):2026-10 · Phase 1 · NCT07426380: A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function2026-10 · Phase 1 · NCT07701083: A Study of Eloralintide (LY3841136) in Healthy Participants2026-12 · Phase 1 · NCT07738614: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight2027-03 · Phase 1 · NCT07401862: A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.2027-03 · Phase 2 · NCT07215559: A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Novo Nordisk

CagriSemaHighest registered phase: Phase 3 · 31 registered Novo Nordisk-sponsored studiesPhase 1: 8 · Phase 2: 4 · Phase 3: 19Registered primary completion dates (registry entries, not company forecasts):2027-03-01 · Phase 3 · NCT07011667: A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term2027-06-09 · Phase 3 · NCT07817251: Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema2027-09-01 · Phase 3 · NCT05669755: REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels2027-10-12 · Phase 1 · NCT07184086: A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet2028-02-23 · Phase 3 · NCT07564414: A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNovo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial

CagrilintideHighest registered phase: Phase 3 · 44 registered Novo Nordisk-sponsored studiesPhase 1: 17 · Phase 2: 5 · Phase 3: 22Registered primary completion dates (registry entries, not company forecasts):2027-01-26 · Phase 1 · NCT07411560: A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese2027-03-01 · Phase 3 · NCT07011667: A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term2027-04-13 · Phase 1 · NCT07557953: A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity2027-05-11 · Phase 3 · NCT07220642: Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide2027-05-12 · Phase 3 · NCT07220759: Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

SemaglutideHighest registered phase: Phase 4 · 94 registered Novo Nordisk-sponsored studiesNot stated: 19 · Phase 1: 30 · Phase 2: 8 · Phase 3: 34 · Phase 4: 3Registered primary completion dates (registry entries, not company forecasts):2026-11-02 · Not stated · NCT07781371: A Retrospective Real-World Cohort Study2027-06-09 · Phase 3 · NCT07817251: Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema2027-08-30 · Not stated · NCT05714683: Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea2027-09-01 · Phase 3 · NCT05669755: REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels2027-09-23 · Phase 1 · NCT07767175: A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Boehringer Ingelheim

SurvodutideHighest registered phase: Phase 3 · 28 registered Boehringer Ingelheim-sponsored studiesPhase 1: 14 · Phase 2: 2 · Phase 3: 12Registered primary completion dates (registry entries, not company forecasts):2026-12-08 · Phase 1 · NCT07768813: A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity2027-01-06 · Phase 1 · NCT05202353: A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver2027-01-08 · Phase 1 · NCT06745284: A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity2027-01-26 · Phase 1 · NCT07407348: A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body2028-01-17 · Phase 3 · NCT07754461: A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarBoehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

Innovent Biologics

MazdutideHighest registered phase: Phase 3 · 19 registered Innovent Biologics-sponsored studiesPhase 1: 3 · Phase 1/2: 3 · Phase 2: 4 · Phase 3: 9Status: Approved by China's NMPA, Jun 27, 2025 (company release)Registered primary completion dates (registry entries, not company forecasts):2026-12-31 · Phase 3 · NCT06884293: A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）2027-05-07 · Phase 3 · NCT06931028: A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m22027-10-31 · Phase 3 · NCT07255209: A Study of IBI362 in Chinese Adolescents With Obesity or OverweightInnovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management

Amgen

Maridebart cafraglutide (MariTide)Highest registered phase: Phase 3 · 27 registered Amgen-sponsored studiesPhase 1: 13 · Phase 2: 3 · Phase 3: 11Registered primary completion dates (registry entries, not company forecasts):2026-11-15 · Phase 1 · NCT07160257: A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus2026-11-18 · Phase 1 · NCT07523711: Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity2027-01-21 · Phase 3 · NCT06858878: Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight2027-01-21 · Phase 3 · NCT06858839: Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight2027-03-23 · Phase 1 · NCT07832799: Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

Zealand Pharma

PetrelintideHighest registered phase: Phase 2 · 5 registered Zealand Pharma-sponsored studiesPhase 1: 3 · Phase 2: 2Registered primary completion dates (registry entries, not company forecasts):2027-04-12 · Phase 1 · NCT07682818: Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic FunctionZealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management

Ask Tina for links to further coverage

Tina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.

Third-party links, listed for reference. Educational information only, not medical advice. Hypnotic Dose does not endorse any product.